Tyche Industries Ltd

Tyche Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating. This change accompanies a downgrade in its Mojo Grade to Strong Sell, reflecting growing concerns over its price attractiveness relative to historical and peer benchmarks.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions and impacts the stock's price attractiveness amid a challenging industry backdrop and mixed financial metrics.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, prompting a downgrade in its Mojo Grade to Strong Sell. With its price-to-earnings (P/E) ratio easing from very expensive to merely expensive, alongside a subdued return profile compared to the Sensex, investors are urged to reassess the stock’s price attractiveness amid evolving market dynamics.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its valuation parameters, moving from fair to very expensive territory. This change, coupled with a recent downgrade to a Strong Sell rating, highlights growing concerns about the stock’s price attractiveness relative to its historical and peer benchmarks.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its recent quarterly financial performance, with key metrics signalling a very negative trend. The company’s latest quarter ending December 2025 saw revenue and profitability contract sharply, intensifying concerns among investors and analysts alike.

Tyche Industries Limited, a Hyderabad-based pharmaceutical manufacturer specialising in Glucosamine Hydrochloride and bulk drug intermediates, reported deeply concerning Q3 FY26 results that underscore accelerating operational deterioration. The company posted net profit of ₹1.82 crores for the quarter ended December 2025, marking a sharp decline of 19.78% quarter-on-quarter and a devastating 61.60% year-on-year contraction. With a market capitalisation of ₹121.00 crores, the micro-cap pharmaceutical player now faces mounting questions about its ability to reverse a multi-quarter downtrend that has seen both revenue and profitability collapse.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. This change, coupled with a recent upgrade in its Mojo Grade to Strong Sell, raises questions about the stock’s price attractiveness amid sector peers and historical benchmarks.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.100 today, marking a significant decline amid a sustained negative trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs 102, marking a significant decline amid a sustained downward trend. The stock has underperformed both its sector and the broader market, reflecting ongoing pressures on its financial performance and valuation metrics.

Tyche Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Tyche Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.104 today, marking a significant milestone in its ongoing decline. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and market sentiment.